TRANSFORM: A 52-week Randomized Placebo-controlled Double-blind Adaptive Phase 2b/3 Trial of Setanaxib with a 52-week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
